Alnylam Pharmaceuticals | ALNY - Equity Capital And Reserves

Stock Price
328.14
Daily Change
-3.10 -0.94%
Monthly
-22.33%
Yearly
18.81%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $233.89M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Moderna USD 9.33B 69M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Takeda JPY 7.64T 513.39B Dec/2025
Tectonic Therapeutic USD 267.53M 16.24M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025
Xencor USD 625.32M 4.96M Sep/2025